Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cardiomyopathy IV: Restrictive Cardiomyopathy

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...

Exercise and Cardiovascular Response

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Transthyretin amyloid polyneuropathy in France: A cross-sectional study with 413 patients and real-world tafamidis meglumine use (2009-2019).

Revue neurologique·2024

Same author

CE-ICP-MS to probe Aβ1-42/copper (II) interactions, a complementary tool to study amyloid aggregation in Alzheimer's disease.

Metallomics : integrated biometal science·2021

Same author

Interactions between copper (II) and β-amyloid peptide using capillary electrophoresis-ICP-MS: Kd measurements at the nanogram scale.

Analytical and bioanalytical chemistry·2021

Same author

In Vitro System for Measuring Chordal Force Changes Following Mitral Valve Patch Repair.

Cardiovascular engineering and technology·2015

Same author

[Cardiac amyloidosis: a case series of 14 patients, description and prognosis].

La Revue de medecine interne·2013

Same author

[Cardiac manifestations of Anderson-Fabry disease and efficacy of enzyme replacement therapy].

La Revue de medecine interne·2011

Search research articles

Related Experiment Video

Updated: Jul 18, 2026

Real-Time Electrocardiogram Monitoring During Treadmill Training in Mice

Real-Time Electrocardiogram Monitoring During Treadmill Training in Mice

Published on: May 5, 2022

[Cardiomyopathy and sport].

¹Service de cardiologie, HEGP, 20, rue Leblanc, 75908 Paris 15. albert.hagege@egp.ap-hop-paris.fr

Archives Des Maladies Du Coeur Et Des Vaisseaux

|December 22, 2006

Summary

Distinguishing physiological from pathological left ventricular hypertrophy (LVH) in athletes is crucial for preventing sudden cardiac death. Echocardiographic measurements and clinical criteria help differentiate these conditions, guiding recommendations for sports participation.

Area of Science:

Cardiology
Sports Medicine
Cardiovascular Imaging

Context:

Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden death in athletes.
Differentiating physiological adaptive changes from pathological hypertrophy is essential in this population.
Athletes training >10 hours/week or competing at younger ages require careful assessment.

Purpose:

To provide clear criteria for distinguishing physiological left ventricular hypertrophy (LVH) from pathological HCM in athletes.
To outline diagnostic pathways for athletes with borderline left ventricular wall thickness.
To establish guidelines for safe sports participation based on echocardiographic findings.

Summary:

Physiological LVH in athletes is typically symmetrical (<13mm), non-obstructive, with normal left ventricular size and minimal left atrial dilatation.

More Related Videos

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

Related Experiment Videos

Last Updated: Jul 18, 2026

Real-Time Electrocardiogram Monitoring During Treadmill Training in Mice

Real-Time Electrocardiogram Monitoring During Treadmill Training in Mice

Published on: May 5, 2022

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

Wall thickness between 13-15mm necessitates further investigation, including stress testing, Holter monitoring, and family history assessment.

LV wall thickness >15mm is considered HCM, mandating cessation of sports; dilated cardiomyopathy should be suspected with LV diameters >60mm and reduced ejection fraction.

Impact:

Enables accurate diagnosis of HCM in athletes, potentially preventing sudden cardiac death.
Guides clinical decision-making regarding sports eligibility for athletes with cardiac abnormalities.
Promotes standardized evaluation protocols for athletes at risk of exercise-induced cardiac events.